

Cardiac Markers in The Early Diagnosis and Management of Patients with Acute Coronary Syndrome

Adjudication Guideline

Rule Category:
Billing

Ref: No:
2017-BR-029

Version Control:
Version No. 2.0

Effective Date:
30/09/2017

Revision Date:
24/12/2024

Approved by:
Daman

Responsible:
Medical Standards
& Research

**Related Adjudication
Guidelines:**
N/A

Table of Contents

1.	Abstract	3
1.1	For Members.....	3
1.2	For Medical Professionals.....	3
2.	Scope	3
3.	Adjudication Policy.....	4
3.1	Eligibility / Coverage Criteria.....	4
3.2	Requirements for Coverage	4
3.3	Non-Coverage.....	4
3.4	Payment and Coding Rules	4
4.	Denial Codes.....	4
5.	Appendices	5
5.1	References	5
5.2	Revision History	5

1. Abstract

1.1 For Members

Chest pain comes in many varieties, ranging from a sharp stab to a dull ache. Some chest pain is described as crushing or burning. In certain cases, the pain travels up the neck, into the jaw, and then radiates through to the back or down one or both arms. Many different problems can cause chest pain. The most life-threatening ones involve the heart (Acute coronary syndrome) or lungs.

1.2 For Medical Professionals

This adjudication rule defines the coverage for cardiac marker tests in diagnosis and risk stratification of patient with chest pain and suspected acute coronary syndrome (ACS).

2. Scope

The scope of this adjudication rule highlights the coverage for Cardiac marker tests in diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS) for health insurance plans administered by Daman subject to policy terms and conditions.

Medical Indications:

Cardiac markers are used in the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS). In patients with suspected acute coronary syndrome (ACS), the following laboratory studies are performed to confirm the diagnosis:

- 1. Troponins:** The troponins are regulatory proteins found in skeletal and cardiac muscle. Cardiac troponin is used in the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS). The cardiac troponins, in particular, have become the cardiac markers of choice for patients with ACS. Indeed, cardiac troponin is central to the definition of acute myocardial infarction (MI) in the consensus guidelines from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC): These guidelines recommend that cardiac biomarkers should be measured at presentation in patients with suspected MI, and that the only biomarker that is recommended to be used for the diagnosis of acute MI at this time is cardiac troponin due to its superior sensitivity and accuracy.
- 2. Creatine Kinase–MB:** Prior to the introduction of cardiac troponins, the biochemical marker of choice for the diagnosis of acute MI was the CK-MB isoenzyme. The criterion most commonly used for the diagnosis of acute MI was 2 serial elevations above the diagnostic cutoff level or a single result more than twice the upper limit of normal. Although CK-MB is more concentrated in the myocardium, it also exists in skeletal muscle and false-positive elevations occur in a number of clinical settings, including trauma, heavy exertion, and myopathy. With the availability of cardiac troponin, CK-MB, myoglobin and other biomarkers are no longer necessary.
- 3. Myoglobin:** Myoglobin is a heme protein found in skeletal and cardiac muscle that has attracted considerable interest as an early marker of MI. With the adoption of a troponin standard for acute MI in the ACC/ESC definition, the sensitivity of myoglobin for acute MI is substantially reduced. This significantly diminishes its utility, and a number of studies have indicated that contemporary cardiac troponin assays render the use of myoglobin measurements unnecessary.

3. Adjudication Policy

3.1 Eligibility / Coverage Criteria

Coverage:

Coverage is subject to SOB's and medically necessary conditions pertaining to Acute Coronary Syndrome and associated conditions when requested for cardiac markers.

Frequency of retesting:

In patients presenting very early (e.g. Within 1 h from chest pain onset), the second cardiac troponin level should be obtained at 3 h, due to the time dependency of troponin release; as late increases in cardiac troponin have been described in 1% of patients, serial cardiac troponin testing should be pursued if the clinical suspicion remains high or whenever the patient develops recurrent chest pain.

3.2 Requirements for Coverage

As per AHA (American Heart Association) up to date release of the Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes with availability of contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin **are not useful** for diagnosis of ACS.

3.3 Non-Coverage

Daman has revised its position on the coverage of both tests and will no longer cover CK-MB and Myoglobin for the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS) for ALL health insurance plans administered by Daman.

3.4 Payment and Coding Rules

CPT code	Code Description
84484	Troponin, quantitative
84512	Troponin, qualitative

4. Denial Codes

Code	Code Description
MNEC-003	Service is not clinically indicated based on good clinical practice
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities

5. Appendices

5.1 References

- <https://www.uptodate.com/contents/initial-evaluation-and-management-of-suspected-acute-coronary-syndrome-myocardial-infarction-unstable-angina-in-the-emergency-department>
- <https://documents.cap.org/documents/cap-cardiac-marker-webinar-handout.pdf>
- <https://www.ncbi.nlm.nih.gov/books/NBK545216/>
- <http://circ.ahajournals.org/content/130/25/e344>
- <https://www.ncbi.nlm.nih.gov/pubmed/9924168>

5.2 Revision History

Date	Change(s)
30/09/2017	Creation of Adjudication Guideline-External Instructions.
24/12/2024	Version 2.0 <ul style="list-style-type: none"> • General Content Review • References Updated

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below: The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.